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Introduction 
C
hronic  infection  with  hepatitis  B  virus 
(HBV)  is  a  major  global  health  problem, 
affecting more than 400 million people worldwide. 
The aim of chronic hepatitis B treatment is to stop 
HBV replication and prevent the development of 
cirrhosis,  liver  insufficiency,  and  hepatocelluler 
carcinoma (1). In chronic hepatitis B (CHB) patients, 
the response criteria are testing positive for HBeAg 
positive, having HBV DNA that become negative 
(virological response), experiencing HbeAg or anti-
HBeAg seroconversion (serological response), having 
ALT  that  turn  normal  (biochemical  response),  or 
recovering  histologically  (2).  In  HBeAg-negative 
patients, the response criteria are the normalizing of 
ALT levels and having negative or undetectible HBV 
DNA levels. Sustained response is the persistence of 
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Background and Aims: We aimed to evaluate the effectiveness of nucleoside analogues such as Lamivudine, Adefovir, 
Entacavir, and Tenofovir in patients with chronic hepatitis B who failed to respond to interferon therapy and relapsed. 
Materials and Methods: We followed a total of 73 patients with hepatitis B in the hepatitis outpatient clinic in our 
hospital. The patients subsequently received nucleoside analogues therapy and their treatment data were evaluated 
retrospectively. The biochemical and virological response rates were evaluated at 3 and 12 months, and we compared 
these results with the results of treatment-naive patients.
Results: There were 29 (39.7%) HbeAg-positive and 44 (60.3%) HbeAg-negative patients, and their mean age was 35.8 
(±13.4) years. Of these patients, 33, 18, 13 and 9 received Entacavir, Tenofovir, Lamivudine, and Adefovir treatment, 
respectively. In HbeAg-negative patients, at 3 months the biochemical and virological response (early response) rates 
were observed to be 91% and 98%), and at 12 months the two rates were 93% and 73%, respectively. In HbeAg-
positive patients, the biochemical and virological response rates at 3 months were 83% and 97%, and the rates at 12 
months were 90% and 48%, respectively. 
Conclusions:  In  CHB  therapy  with  treatment-resistent  patients,  nucleoside  analogues  may  be  preferable.  There 
are disadvantages to nucleoside analogues, such as a risk of developing resistance during therapy, reduced HBeAg 
seroconversion compared to interferons, and the therapy’s ambiguous duration. In our study, in HbeAg-negative patients 
who received nucleoside analogues, a lower biochemical response rate was detected in patients with 1 year of Lamivudine 
therapy compared to other therapies.  For HbeAg-positive patients, the virological response rate was higher in 1 year of 
Tenofovir therapy than with other therapies. 
Keywords: Hepatitis B Virus; nucleoside analogues; interferon therapy Hepat Mon. 2010; 10(4): 289-293
290 Nucleoside Analogues and Hepatitis B
a response to therapy for 6 months after the therapy 
is discontinued. In patients for whom therapy was 
initiated,  the  absence  of  virological,  serologic,  or 
biochemical responses implies unsuccessful therapy; 
however,  for  patients  who  respond  at  the  end  of 
therapy, HBV DNA becoming positive, the elevation 
of  ALT,  or  reversion  (repositivity  of  HBeAg)  are 
considered relapses. HBV DNA that were negative 
during  therapy  but  become  positive  afterwards  is 
a sign of viral “breakthrough” (2). Interferons have 
been used in the treatment of chronic hepatitis B 
for many years. In early studies; various therapies 
were provided to patients with previous treatment 
failures,  with  variable  success  rates. Therapies  for 
patients  with  failed  interferon  therapy  include 
retreatment with standard interferon, a combination 
of  interferon  and  Lamivudine,  a  combination  of 
hepatitis B surface antigen vaccination and interferon, 
pegylated interferon, a combination of  pegylated 
interferon  and  Lamivudine,  Lamivudine  by  itself, 
and Adefovir. Unfortunately, the response rate with   
those treatment methods  was not high (3). Today, 
interferons (conventional and pegylated), nucleoside 
analogues (Lamivudinee, Entacavir, telbuvidin, and 
emstrisitabin), and nucleotide analogues (Adefovir 
and  Tenofovir)  are  used  in  CHB  treatment. 
Among  these  treatment  options,  conventional 
Interferons (IFN), Pegylated Interferons (peg-IFN), 
Lamivudinee  (LAM),  Adefovir  (ADV),  Entacavir 
(ETV), and Tenofovir (TDF) are the drugs available 
and approved for use in Turkey. In the literature, 
there is no study that compares the effectiveness of 
nucleozide-analogue therapies in cases unresponsive 
to IFN. In the present study, we evaluated the annual 
effectiveness  of  Lamivudinee,  Adefovir,  Entacavir, 
and  Tenofovir  in  CHB  patients  who  failed  to 
respond to conventional or Pegylated IFN therapy 
and developed relapses, and we compared our results 
with treatment-naive patients.
Materials And Methods 
We retrospectively evaluated a total of 73 patients 
with hepatitis B in the hepatitis  outpatient clinic 
affiliated with the Department of Infectious Diseases 
and  Clinical  Microbiology  of  the  Izmir  Tepecik 
Training  and  Research  Hospital  who  previously 
failed to respond to classic or peg-IFN therapy or 
developed relapses and were subsequently treated with 
nucleoside analogues. Of the the experimental group, 
33 (45.2%) received Entacavir, 18 (24.6%) received 
Tenofovir, 13 (17.8%) received Lamivudinee, and 
9  (12.3%)  received  Adefovir  therapy,  respectively. 
None of the patients who were included in the study 
had previously received another nucleoside analogues 
therapy. We composed the control group with naive 
patients who did not recieve IFN or other antiviral 
agents before treatment with nucleozide analogues. 
Of the control group, 15 (34,8%) received Entacavir, 
21 (%48,8%) received Tenofovir, 5 (11,6%) received 
Lamivudinee, and 2 (4,6%) received Adefovir. We 
compared the experimental group with the control 
group. Patients’ liver function, HBeAg, anti-HBe, 
and HBV DNA levels were monitored for 3 months. 
During  treatment,  biochemical  and  virological 
response rates were evaluated at 3 and 12 months. 
For this study, we used the VHSD Guidelines for 
Viral Hepatitis Diagnosis and Treatment (2009) to 
define biochemical response  as the normalization of 
ALT (<35 IU/mL), serological response as HbeAg or 
anti-HBe  seroconversion;  and  virological  response 
as at least a 2-logarithmic decrease in HBV DNA 
at 3 months and HBV DNA reaching negative or 
undetectible  levels  by  12  months.  We  classifed 
patients as unresponsive to treatment if they did not 
fit these criteria. First-year Lamivudinee and Adefovir 
resistance were determined. Statistical analyses were 
performed using Fisher’s chi-square tests, McNemar’s 
test, and  t-tests. This study was conducted with the 
approval of the ethics committee of Tepecik Research 
and Educational Hospital.
Results
In  the  experimental  group,  27 ( 37%)  and  46 
(63%) of the total 73 CHB patients were female 
and male, respectively. The patients’ mean age was 
35.8 years (±13.4). There were 29 (39.7%) HBeAg-
positive and 44 (60.3%) HBeAg-negative patients 
in the group. Previously, 36 patients (49.3%) had 
received classic IFN therapy and 37 (50.7%) received 
peg-IFN therapy due to CHB. In the control group, 
21 (50%) and 21 (50%) of the total 42 CHB patients 
were  female  and  male,  respectively.  The  patients’ 
mean  age  was  34.8  years  (±11.9). There  were  19 
(45.2%) HBeAg-positive and 23 (54.8%) HBeAg-
negative patients in the group. The biochemical and 
virological responses at the end of 3 and 12 months 
are given in tables 1 and 2 according to the therapies 
given to the patients in the experimental group and 
the control group who were HBeAg negative and 
positive, respectively. 
In HbeAg-negative patients, whereas a significant 
difference was not found between therapies in terms 
of a biochemical response at 3 months or a virological 
response at 3 or 12 months (P>0.05), the biochemical 
response  at  12  months  was  significantly  lower  in 
the Lamivudinee group compared to the Adefovir, Hepat Mon. 2010; 10(4): 289-293
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Tenofovir,  and  Entacavir  groups  (P≤0.05).  The 
biochemical response at 3 months in HBeAg-negative 
patients who recieved Tenofovir and Adefovir in the 
experimental group were signigficantly higher than 
the control group (P≤0.05). The biochemical response 
at 12 months in patients who recieved Adefovir in the 
experimental group was signigficantly higher than the 
control group (P≤0.05). In HbeAg-positive patients, 
whereas there were no significant differences between 
therapies in terms of the biochemical response at 3 
months; a virological response at 3 or 12 months; 
or virological and serological responses at 12 monhts 
(P>0.05),  an  elevated  virological  response  was 
observed in the Tenofovir group at 1 year compared 
to the Lamivudinee, Adefovir, and Entacavir groups 
(P≤0.05). Only 1 patient who used Adefovir in the 
HBeAg-positive  group  did  not  have  a  virological 
response by 12 months. There was no significant 
difference statistically (P>0.05). Virological response 
at  12th  month  in  HBeAg  positive  patients  who 
recieved  Tenofovir  in  experimental  group  were 
signigficantly higher than control group (P≤0.05). 
HbeAg seroconversion in HBeAg positive patients 
who recieved Tenofovir and Entacavir in experimental 
group were signigficantly higher than control group 
(P≤0.05). In the experimental and control groups, 
the  mean  ALT,  HBV  DNA,  and  HAI  levels  at 
baseline, 3 months, and 12 months of treatment are 
shown in table 3.
The mean ALT, HBV DNA, and HAİ levels at 
the  beginning  of  treatment  were  not  significantly 
different  between  the  experimental  and  control 
groups ( P>0.05).  In  the  HBeAg-positive  patients, 
whereas the mean ALT levels were not significantly 
different  between  the  experimental  and  control 
groups at 3 or 12 months (P>0.05), the mean HBV 
DNA levels were found to be significantly lower in 
the experimental group (P≤0.05).  In the HBeAg-
negative  patients,  whereas  the  mean  HBV  DNA 
levels were not significantly different between the 
experimental and control groups at both timepionts 
(P>0.05) at 3 or 12 months, the mean ALT levels 
were significantly lower in the experimental group at 
both timepoints (P≤0.05). In the experimental and 
control groups, the comparisons of the bichemical, 
virological, and serological responses and confidence 
intervals (CI 95%) are shown in table 4.
YMDD and YVDD mutations developed in 2 
(11.7  %)  Lamivudine-treated  patients.  Entakavir 
and Tenofovir resistance were not examined.
Discussion
In  the  previous  studies,  for  patients  who  were 
unresponsive  to  IFN  therapy,  IFN  therapy  was 
retried, but in these studies the number of subjects 
was generally small. Repeated IFN therapy in patients 
who fail to respond may cause HBeAg seroconversion, 
and the patient’s HBV DNA can became negative. In 
Table 2. The percentage of response against antiviral therapy in the patients with HBeAg 
positive and unpresponsive to IFN
Experimental group   Control group
Drug n Virological 
response
Biochemical 
response n Virological 
response
Biochemical 
response
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
Lamivudine 8 87,5 25 62,5 87,5 2 66,7 50 100 100
Adefovir  1 100 0 100 100 0 0 0 0 0
Tenofovir 6 100 100 83,3 100 8 100 37,5 62,5 87,5
Entacavir 14 85,7 42,9 82,9 100 9 100 66,7 66,7 88,9
Total 29 89,7 48,3 82,8 96,6 19 100 52,6 68,4 89,4
Table 1. The percentage of response to antiviral therapy in the patients with HBeAg 
negative and unpresponsive to IFN
Experimental group Control group
Drug n Virological 
response
Biochemical 
response n Virological 
response
Biochemical 
response
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
3rd mo 
(%)
12th mo 
(%)
Lamivudine 5 80 60 100 80 3 66,7 33,3 100 100
Adefovir  8 87,5 50 100 100 1 100 0 0 0
Tenofovir 12 100 100 83,3 100 13 100 76,9 30,8 76,9
Entacavir 19 94,7 68,4 89,5 100 6 100 83,3 66,7 100
Total 44 93,2 72,7 90,9 97,7 23 95,6 82,6 47,8 82,6Hepat Mon. 2010; 10(4): 289-293
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HBeAg-negative patients who fail to respond to IFN 
therapy, HBV DNA negativity can be achieved in up 
to 22% of patients by repeating the IFN treatment   
(2, 4, 5). In cases unresponsive to IFN, IFN + Lamivudine 
has been shown to be superior to IFN monotherapy in 
terms of HBV DNA becoming negative and HBeAg 
seroconversion  (2,  6-8).  In  HBeAg-positive  patients 
who  fail  to  respond  to  IFN  therapy,  HBV  DNA 
negativity can be achieved in up to 29.4% of patients 
with Lamivudine therapy. In a study carried out with 
HBeAg-positive children who failed to respond to IFN 
therapy, HBV DNA negativity was obtained in 44% 
and HBeAg seroconversion in 5% for patients through 
Lamivudine therapy (9). During this study, long-term 
Lamivudine results were evaluated. Four years after 
starting Lamivudine treatment, most children from this 
study were off Lamivudine, mainly because of lack of 
compliance and poor HBe seroconversion (10). Again, 
in another study conducted on pediatric group with 
a one-year Lamivudine therapy, an HBeAg/antiHBe 
seroconversion rate of was detected in 10% of cases 
unresponsive to IFN (11). In some studies, the therapy 
responses obtained by Lamivudine in patients who are 
unresponsive to IFN were similar to those obtained 
in naïve patients. Schiff et al. compared Lamivudine 
and Lamivudine+IFN therapy in 238 HBeAg-positive 
patients who were unresponsive to IFN therapy with 
a placebo control group. A higher ALT-normalization 
was  found  in  the  Lamivudine  monotherapy  group 
(44%) compared to the combination therapy group 
(18%) and the placebo group (15%). Loss of HBeAg 
was established as 33%, 23%, and 13%, respectively. 
Histologic recovery was determined to be 52% in the 
Lamivudine group, 32% in the combination group, 
and 25% in the placebo group (8).  In a study carried 
out in Turkey, 2 years of Lamivudine monotherapy 
and  Lamivudine+IFN  combination  therapy  were 
compared  in  HBeAg-negative  CHB  patients  who 
were unresponsive to IFN. The therapy response was 
29.2% in those receiving Lamivudine monotherapy 
and  19%  in  those  receiving  Lamivudine+IFN 
combination therapy. The YMDD mutation rate at 
the end of 2 years was found to be 59.2% in the first 
group  and  62.5%  in  the  second  group  (12). These 
findings suggest that the use of Lamivudine therapy 
in patients who fail to respond to IFN therapy would 
be helpful.  In two different studies, Adefovir was 
attempted  in  123  HbeAg-positive  and  48  HbeAg-
Table 3. Comparison of mean levels of ALT, HBV DNA, and HAI at baseline, 3 months, and 
12 months of treatment
Experimental group Control group
HBeAg(+) HBeAg(-) HBeAg(+) HBeAg(-)
The begining
ALT
(IU/L)
84.1 (±56.3) 131.7 (100.2) 122.1 (±129.7) 99.7 (±63.7)
HBVDNA
(Copy/ml)
7x107(±5.3x107) 1.8x107(±3.5x107) 8.3x107(±3.4x107) 7.5x107(±1.6x108)
HAİ 8.4 (±3.6) 9.5 (±3.9) 9.4 (±3.3) 8.4 (±3.8)
3rd mo
ALT
(IU/L)
32.7(±17.6) 27.4(±10.7) 46.9(±50.4) 52.8(±38.5)
HBVDNA
(Copy/ml)
6.4x103(±6.8x103) 2.5x103(±2.3x103) 6.7x104(±9.5x104) 2.5x104(±1.2x107)
12th mo
ALT
(IU/L)
26.3(±6.8) 24.0(±4.9) 25.3(±7.3) 33.2(±17.5)
HBVDNA
(Copy/ml)
2.3x102(±4.7x102) 1.2x102(±3.3x102) 5.9x102(±7.1x102) 2.1x103(±9.5x103)
Table 4. Comparison of bichemical, virological, and serological responses and confidence 
intervals
HBeAg status Experimental group Control group OR CI (95%)
3rd mo VR
(%)
+ 89.7 100 1.115 0.986-1.262
- 93.2 95.7 0.621 0.061-6.332
12th mo VR
(%)
+ 48.3 52.6 0.840 0.264-2.675
- 72.7 69.6 1.167 0.385-3.535
3rd mo BR
(%)
+ 82.8 68.4 2.215 0.566-8.678
- 90.6 47.8 10.9 2.933-40.580
12th mo BR
(%)
+ 96.6 89.5 3.294 0.277-39.138
- 97.7 82.6 9.053 0.948-86.479
12th mo SR (%) + 13.8 0 - -Hepat Mon. 2010; 10(4): 289-293
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negative patients who received IFN previously and 
failed  to  respond.  An  HBeAg  seroconversion  rate 
similar  to  the  response  rates  in  naïve  patients  was 
found. After administration of Adefovir, the HBeAg 
seroconversion  rates  in  patients  treated  previously 
with interferon were similar to those in naïve patients 
(13,  14).  Entakavir  has  been  tried  on  cases  who 
received IFN previously but not Lamivudine, and it 
has been shown to be effective (13). In CHB therapy 
for patients who fail to respond or develop relapses 
after  interferon  treatment,  nucleous(t)id  analogues 
may be preferable. There are disadvantages, such as a 
risk of developing resistance during therapy, reduced 
HBeAg seroconversion compared to interferons, and 
the ambiguity of the therapy’s duration. In our study, 
whereas the 1-year response rate was good (72.7%) 
in  HBeAg-negative  patients  who  failed  to  respond 
to  interferon  therapy  and  received  nucleous(t)id 
analogues, reduced serologic (13.8%) and virological 
response  (48%)  rates  were  observed  in  HBeAg-
positive  patients.  However,  antiviral  agents  are  still 
an important choice as an alternative drug in CHB 
therapy for patients who are unresponsive to IFN. In 
the literature, no previous study had compared the 
effectiveness of nucleozid-analogues therapies in cases 
unresponsive to IFN. In our study, we compared the 
1-year effectiveness of lamuvudin, Adefovir, entakavir, 
and Tenofovir. After 1 year of therapy, a significantly 
lower  biochemical  response  rate  was  found  in  the 
Lamivudine  group  compared  to  other  groups,  and 
the virological response rate was significantly higher 
in the Tenofovir group than the other groups. As a 
result, our contention is that this study can inform 
nucleozid-analogues therapy for patients who fail to 
respond to IFN and develop relapses.  Finally, much 
more studies are needed in this regard. 
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